Home › Funds › Defilade Capital Management, L.P. › BMRN
Defilade Capital Management, L.P. position in BMRN
BIOMARIN PHARMACEUTICAL INC · Health Care
Defilade Capital Management, L.P. reported holding 682,005 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q2 2026 13F filing — a position valued at US$39.0M, representing 5.22% of its reported portfolio and ranking #4 among its reported holdings. Defilade Capital Management, L.P. first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s BMRN position evolved
Defilade Capital Management, L.P. first disclosed a stake in BMRN in Q2 2026 at 682,005 shares (US$39.0M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 682.00K | $39.02M | New |
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held BMRN?
Defilade Capital Management, L.P. has disclosed BMRN holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Defilade Capital Management, L.P.'s current position in BMRN?
As of Q2 2026, Defilade Capital Management, L.P. holds 682.00K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $39.02M, representing 5.22% of its reported portfolio and ranking #4.
Has Defilade Capital Management, L.P. been buying or selling BMRN?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. newly opened its position in BMRN.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.